Instead of physical forms and shapes, nuclear medicine imaging takes photos based on the chemistry of the human body. Due to the rising prevalence of target illnesses, the technology is seeing a spike in usage. Several hospitals combine nuclear medicine images with MRI (Magnetic Resonance Imaging) or CT (Computed Tomography) to create distinct views (image fusion), allowing doctors to associate and interpret data from two different tests on a single image, resulting in more accurate information and precise diagnoses.
In the last decade, there has been a major evolution of hybrid systems due to technological breakthroughs in the field of imaging. The use of integrated PET modalities is a significant advancement in this area. The PET/CT modality has been so successful in terms of innovation that major imaging system manufacturers no longer offer solo PET systems. Furthermore, one of the key drivers for the market is the growth in the occurrence of cancer and cardiac diseases. Nuclear medicine has a lot of potential for treating cancer and heart disease. There is substantial evidence that using nuclear imaging techniques to diagnose a tumour has a greater influence on patient management in terms of tumour surveillance and treatment response.
Nuclear imaging systems are expensive and take a lot of money to set up, which drives up the cost of the procedure for patients. This has an impact on the rate of adoption of new systems, particularly in developing nations; as a result, most healthcare facilities in these nations are unable to purchase such systems. A PET system costs between USD 400,000 and USD 600,000 in rising nations like Brazil, while a SPECT system costs between USD 250,000 and USD 400,000. The market’s growth is likely to be hampered by these high expenses, which will be compounded by maintenance costs.
Based on product, the market is fragmented into SPECT Imaging Systems, PET Imaging Systems, and Planar Scintigraphy Imaging Systems. The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems. The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems
Based on the application, the market is fragmented into oncology, cardiology, neurology, and others. Owing to the rising incidence and prevalence of cancer across the globe, initiatives taken by public and private organizations to curb the rising cancer prevalence, and the development of advanced systems and radiotracers for oncology.
Based on end-users, the market is fragmented into hospitals, imaging centers, academic & research centers, and others. The SPECT imaging systems segment is further categorized into standalone and hybrid imaging systems.
For a better understanding of the market adoption of the Nuclear Medicine Imaging market, the market is analyzed based on its worldwide penetration in the countries such as North America (United States, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the nuclear medicine imaging industry and generated revenue of USD XX million in 2020 owing to the increasing incidence of chronic diseases, and improvement of healthcare systems in the region. However, the Asia Pacific region would grow at the highest CAGR during the forecast period.
Some of the major players operating in the market include Siemens Healthineers, GE Healthcare, Philips, Digirad Corporation, Mediso Medical Imaging Systems, Positron Corporation, Cardinal Health Inc., Bracco Imaging SpA, Hitachi Medical Corporation, Canon Medical Systems Corporation, etc. Several M&A’s along with partnerships have been undertaken by these players to boost their presence in different regions.
TABLE OF CONTENTS
1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Nuclear Medicine Imaging Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Nuclear Medicine Imaging Market
2.1.1 Main Objective of the Nuclear Medicine Imaging Market
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 TOP START-UPS UNDER NUCLEAR MEDICINE IMAGING SECTOR
6 NUCLEAR MEDICINE IMAGING AMID COVID-19
7 GLOBAL NUCLEAR MEDICINE IMAGING MARKET REVENUE (USD BN), 2019-2027F
8 MARKET INSIGHTS BY PRODUCT
8.1 SPECT Imaging Systems
8.2 Hybrid SPECT Imaging Systems
8.3 Standalone SPECT Imaging Systems
8.4 PET Imaging Systems
8.5 Planar Scintigraphy Imaging SystemsA
9 MARKET INSIGHTS BY APPLICATION
10 MARKET INSIGHTS BY END-USER
10.2 Imaging Centers
10.3 Academic & Research Centers
11 MARKET INSIGHTS BY REGION
11.1 NORTH AMERICA NUCLEAR MEDICINE IMAGING MARKET
11.1.1 United States
11.1.3 Rest of North America
11.2 EUROPE NUCLEAR MEDICINE IMAGING MARKET
11.2.3 United Kingdom
11.2.6 Rest of Europe
11.3 ASIA-PACIFIC NUCLEAR MEDICINE IMAGING MARKET
11.3.5 Rest of Asia Pacific
11.4 REST OF WORLD NUCLEAR MEDICINE IMAGING MARKET
12 NUCLEAR MEDICINE IMAGING MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
12.3 Impact Analysis
13 NUCLEAR MEDICINE IMAGING MARKET OPPORTUNITIES
14 NUCLEAR MEDICINE IMAGING MARKET TRENDS
15 LEGAL & REGULATORY FRAMEWORK
16 DEMAND AND SUPPLY SIDE ANALYSIS
16.1 Demand Side Analysis
16.2 Supply Side Analysis
16.2.1 Top Product Launches
16.2.2 Top Business Partnerships
16.2.3 Top Business Expansions, Investments and Divestitures
16.2.4 Top Merger and Acquisitions
17 VALUE CHAIN ANALYSIS
18 COMPETITIVE SCENARIO
18.1 Porter’s Five Forces Analysis
18.1.1 Bargaining power of Supplier
18.1.2 Bargaining power of Buyer
18.1.3 Industry Rivalry
18.1.4 Availability of Substitute
18.1.5 Threat of new Entrants
18.2 Competitive Landscape
18.2.1 Company Shares, By Revenue
19 COMPANY PROFILED
19.1 Siemens Healthineers
19.2 GE Healthcare
19.4 Digirad Corporation
19.5 Mediso Medical Imaging Systems
19.6 Positron Corporation
19.7 Cardinal Health Inc.
19.8 Bracco Imaging SpA
19.9 Hitachi Medical Corporation
19.10 Canon Medical Systems Corporation
20 DISCLAIMER —-
+44 203 500 2763
+1 62 825 80070
Note: The Heraldkeeper News Department was not involved in the creation of this content.
If you have any problem with this press release? Contact the source provider Heraldkeeper.com, you can contact them here.